The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.

PARSIPPANY, N.J. — Multiple federal and state agencies are investigating a possible arson attempt at the New Jersey home of an executive of global pharmaceutical giant Bayer, authorities said.

Bayer shares were down 6.3% at 1330 GMT as investors ... a 2023 development setback for its most promising experimental medicine, weak agriculture markets and pressure from some investors to ...

Even though sales of prostate cancer drug Nubeqa and chronic kidney disease medicine Kerendia are picking up, they are not as profitable as Xarelto. Bayer’s Xarelto blood thinner medicine once ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

After years of buying Adalat to control her high blood pressure, Beijing woman Sophie Chen started noticing from 2023 that the medication – produced by German pharmaceutical company Bayer ...

Bayer is on the brink of filing a new MRI contrast ... one of the most powerful diagnostic tools in contemporary clinical medicine, offering unparalleled insight into the human body," said QUANTI ...

The global nuclear medicine market is expanding rapidly, thanks to advances in diagnostic imaging and targeted treatments.

Bayer will seek shareholder approval to raise equity capital worth close to 35% of its outstanding shares over the next three ...